On November 17, 2025 Daan Biotherapeutics reported that it has signed a Memorandum of Understanding (MOU) with Triore to establish a mutual cooperation system in the field of antibody-drug conjugates (ADCs).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Accordingly, through this agreement, the two companies agreed to cooperate in various areas of collaboration, including the exchange of antibody-based new drug technologies, the discovery and evaluation of ADC candidates, and the expansion of future joint research and development.

In particular, we plan to lay the foundation for the development of next-generation ADC drugs by sharing technological and research capabilities based on mutual trust.

Cho Byung-chul, CEO of Daan Biotherapeutics, stated, "The combination of Daan Biotherapeutics’ target discovery platform and antibody development technology with Triore’s proprietary antibody-drug conjugate platform will enable the early securing of a globally competitive ADC pipeline," adding, "We expect to significantly expand the potential for developing innovative new drugs through our collaboration with Triore."

"Through collaboration with Daan Biotherapeutics, Triore’s innovative ADC platform can now be combined with a broader range of antibody assets, and we look forward to the development of next-generation anticancer treatments based on mutually complementary capabilities through this agreement," said Woo Seong-ho, CEO of Triore.

(Press release, TriOar Biotechnology, NOV 17, 2025, View Source;idx=11 [SID1234664819])